Merck Sharp + Dohme Corp.

Fmc Corporation

Msd K.k.

Michael A Rossi

Jun Liang

Mark E Layton

Joseph E Pero

Michael J Kelly, Iii

Dansu Li

Wenming Zhang

Scott E Wolkenberg

Lianyun Zhao

James J Mulhearn

Kevin F Gilbert

Pablo De Leon

Hannah D Fiji

Hannah D G F Lehman

Christopher D Cox

Yasuhiro Goto

Toshihiro Sakamoto

Philip E Sanderson

Izzat Tiedje Raheem

Anthony J Roecker

Yoshio Ogino

Jiabing Wang

Michael J Breslin

Zhijian Zhao

Essa H Hu

Jeffrey Curtis Kern

Hidetomo Furuyama

Nobuhiko Kawanishi

Timothy John Hartingh

Takashi Mita

Yiwei Li

Kevin J Rodzinak

Alexander J Reif

Yu Onozaki

Kasinath Sana

Laura Vassallo

Donna J Armstrong

Swati I P Mercer

Michael J Iii Kelly

Swati Pal Mercer

Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, (I) wherein A, X, X, Xand Xare as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention. 

Heterocycle-substituted bicyclic azole pesticides

Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein and A, R, m, X, X, X, X, Y, Yand Yare as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.

Disclosed are compounds of Formula A: Formula A, or a salt thereof, wherein 'Het', R, and Rare defined herein, which have properties for blocking Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating neuropathic pain disorders using the same. 

Benzoxazolinone compounds with selective activity in voltage-gated sodium channels

Disclosed are compounds of Formula Aand Formula A: wherein 'Heteroaryl-1', R, R, R, and Rare defined herein, which novel compounds have properties for blocking Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formulae Aand Aor their salts, and methods of treating neuropathic pain disorders using the same. 

N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels

The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluRreceptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

Imidazopyridin-2-one derivatives

Disclosed are compounds of Formula (A) or a salt thereof, wherein 'Het', R, and Rare defined herein, which have properties for blocking Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (A) or their salts, and methods of treating neuropathic pain disorders using the same. 

The present invention is directed to aryloxymethyl cyclopropane derivatives which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Aryloxmethyl cyclopropane derivatives as PDE10 inhibitors

The instant invention provides for substituted [1,2,4]triazolo[4,3-a]-1,5-naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity, especially Akt1 by administering the compound to a patient in need of treatment of cancer.

Inhibitors of AKT activity

Growing community of inventors

Limerick, PA, United States of America

Michael A Rossi